Verition Fund Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.29M | Buy |
+22,500
| New | +$1.23M | 0.01% | 1330 |
|
|
2026
Q1 | – | Sell |
-86,600
| Closed | -$5.15M | – | 2394 |
|
|
2025
Q4 | $5.15M | Sell |
86,600
-70,145
| -45% | -$3.82M | 0.02% | 854 |
|
|
2025
Q3 | $8.49M | Sell |
156,745
-134,733
| -46% | -$7.71M | 0.04% | 638 |
|
|
2025
Q2 | $16M | Buy |
291,478
+183,821
| +171% | +$10.8M | 0.07% | 307 |
|
|
2025
Q1 | $7.61M | Buy |
107,657
+45,079
| +72% | +$3.03M | 0.04% | 595 |
|
|
2024
Q4 | $4.11M | Buy |
62,578
+11,281
| +22% | +$756K | 0.02% | 1028 |
|
|
2024
Q3 | $3.61M | Sell |
51,297
-21,680
| -30% | -$1.81M | 0.02% | 1053 |
|
|
2024
Q2 | $6.01M | Buy |
72,977
+3,605
| +5% | +$300K | 0.03% | 614 |
|
|
2024
Q1 | $6.06M | Buy |
69,372
+1,719
| +3% | +$154K | 0.04% | 553 |
|
|
2023
Q4 | $6.52M | Buy |
67,653
+1,477
| +2% | +$131K | 0.05% | 364 |
|
|
2023
Q3 | $5.86M | Sell |
66,176
-5,122
| -7% | -$456K | 0.07% | 378 |
|
|
2023
Q2 | $6.18M | Sell |
71,298
-64,519
| -48% | -$6.07M | 0.08% | 312 |
|
|
2023
Q1 | $13.2M | Sell |
135,817
-65,018
| -32% | -$6.74M | 0.18% | 145 |
|
|
2022
Q4 | $20.8M | Sell |
200,835
-47,834
| -19% | -$4.49M | 0.32% | 62 |
|
|
2022
Q3 | $21.1M | Sell |
248,669
-17,306
| -7% | -$1.54M | 0.24% | 77 |
|
|
2022
Q2 | $22M | Buy |
265,975
+75,450
| +40% | +$6.01M | 0.44% | 18 |
|
|
2022
Q1 | $14.7M | Buy |
190,525
+126,039
| +195% | +$10.5M | 0.18% | 92 |
|
|
2021
Q4 | $5.7M | Sell |
64,486
-294
| -0.5% | -$24.3K | 0.04% | 308 |
|
|
2021
Q3 | $5.01M | Sell |
64,780
-102
| -0.2% | -$8.05K | 0.04% | 276 |
|
|
2021
Q2 | $5.41M | Buy |
+64,882
| New | +$5.14M | 0.05% | 227 |
|
|
2021
Q1 | – | Sell |
-134,585
| Closed | -$11.8M | – | 1553 |
|
|
2020
Q4 | $11.8M | Sell |
134,585
-44,738
| -25% | -$3.55M | 0.1% | 120 |
|
|
2020
Q3 | $13.6M | Buy |
+179,323
| New | +$18.1M | 0.27% | 62 |
|
|
2020
Q2 | – | Sell |
-100,308
| Closed | -$9.97M | – | 1062 |
|
|
2020
Q1 | $8.48M | Buy |
100,308
+4,288
| +4% | +$369K | 0.33% | 58 |
|
|
2019
Q4 | $8.12M | Buy |
96,020
+79,615
| +485% | +$6.01M | 0.15% | 112 |
|
|
2019
Q3 | $1.1M | Sell |
16,405
-5,137
| -24% | -$396K | 0.03% | 387 |
|
|
2019
Q2 | $1.84M | Sell |
21,542
-14,197
| -40% | -$1.21M | 0.05% | 256 |
|
|
2019
Q1 | $3.17M | Sell |
35,739
-44,372
| -55% | -$4.11M | 0.12% | 116 |
|
|
2018
Q4 | $6.82M | Buy |
80,111
+77,983
| +3,665% | +$7.42M | 0.49% | 39 |
|
|
2018
Q3 | $206K | Buy |
+2,128
| New | +$212K | 0.01% | 1165 |
|
|
2017
Q4 | – | Sell |
-10,272
| Closed | -$956K | – | 896 |
|
|
2017
Q3 | $956K | Buy |
+10,272
| New | +$908K | 0.08% | 313 |
|
|
2017
Q2 | – | Sell |
-2,577
| Closed | -$226K | – | 945 |
|
|
2017
Q1 | $226K | Buy |
+2,577
| New | +$229K | 0.02% | 986 |
|
|
2016
Q4 | – | Sell |
-3,961
| Closed | -$366K | – | 1172 |
|
|
2016
Q3 | $366K | Sell |
3,961
-4,070
| -51% | -$383K | 0.04% | 658 |
|
|
2016
Q2 | $625K | Buy |
8,031
+180
| +2% | +$15.3K | 0.08% | 305 |
|
|
2016
Q1 | $648K | Buy |
7,851
+5,859
| +294% | +$477K | 0.1% | 249 |
|
|
2015
Q4 | $209K | Sell |
1,992
-423
| -18% | -$44.2K | 0.04% | 381 |
|
|
2015
Q3 | $254K | Buy |
+2,415
| New | +$323K | 0.07% | 393 |
|
|
2015
Q1 | – | Sell |
-2,336
| Closed | -$248K | – | 394 |
|
|
2014
Q4 | $211K | Buy |
+2,336
| New | +$194K | 0.05% | 231 |
|
|
2013
Q4 | – | Sell |
-6,928
| Closed | -$500K | – | 510 |
|
|
2013
Q3 | $500K | Sell |
6,928
-2,271
| -25% | -$151K | 0.08% | 212 |
|
|
2013
Q2 | $513K | Buy |
+9,199
| New | +$573K | 0.09% | 227 |
|
Other funds holding BMRN
VPC
Verition Fund Management's BMRN Position: Q2 2026 in Review
Verition Fund Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 22,500 shares worth $1.29M. The stake represents 0.01% of the portfolio and ranks #1330 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in BMRN as recently as Q4 2025.
Verition Fund Management first reported a position in BMRN in Q2 2013 and has held it in 39 quarters since. The position peaked at $22M in Q2 2022. 562 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- Verition Fund Management held 22,500 shares of BioMarin Pharmaceuticals worth $1.29M as of Q2 2026.
- BioMarin Pharmaceuticals was a new Verition Fund Management position in Q2 2026.
- BioMarin Pharmaceuticals made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #1330 holding.
- Verition Fund Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 39 quarters since.
- Verition Fund Management's BioMarin Pharmaceuticals position peaked at $22M in Q2 2022.
- 562 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.